Member Info for Num4

Confirming really what we all think, new vaccines each year, potentially 6monthly, treatments forever.
Take the money that we will soon make from Sareum and invest in yourself, stay fit and well for this new world, quit smoking and stay healthy.

Sanofi saw enough potential in the concept to bet $125 million on an asset that is yet to be tested in humans. The deal, which features more than $1 billion in potential milestones, gives Sanofi exclusive global rights to BND-22.

Biond is gearing up to start a first-in-human clinical trial of the checkpoint inhibitor by the middle of 2021. Having recently submitted an IND to the FDA, Biond will lead the phase 1a assessment of the drug, both as a monotherapy and in combination with other cancer therapies, before handing off to Sanofi for further development.

https://www.fiercebiotech.com/biotech/sanofi-pays-125m-to-take-lead-new-checkpoint-inhibitor-space

Preclinical, £125million upfront and billion in milestones.

Deals are happening people, hold tight for ours. I actually expect it to be more than this single deal, so the TO value is obviously more than this.
Larger buys still coming through and only a matter of time.

https://endpts.com/amgen-ponies-up-240m-for-michigan-discovery-outfits-dendritic-cell-based-molecules-for-autoimmune-disorders/

Quote MHRA
"The authorisation of the Pfizer/BioNTech vaccine was done using a regulatory process known as a ‘rolling review’. A ‘rolling review’ can be used to complete the assessment of a promising medicine or vaccine during a public health emergency in the shortest time possible. This is done as the packages of data become available from ongoing studies on a staggered basis. The temporary authorisation under Regulation 174 permits the supply of identified COVID-19 mRNA Vaccine BNT162b2 batches, based on the safety, quality and efficacy data submitted by Pfizer/BioNTech to MHRA in the period from 1 October to 2 December 2020.



MHRA would consider other medicines or vaccines under the rolling review process, if they were considered suitable for this process. In the first instance, we would ask that any company wishing to gain authorisation of a medicinal product via this route contact MHRA for a scientific advice meeting. The contact details are provided below:
"

Just shows that when the bad news hits, multiple "watchers" come from their rocks, holding for years, and choose now to push negativity for a compound that was resurrected. The joys of AIM and the wretches that patrol trying to cast doubt for their own gain.
This will have almost no impact on the immediate future for Sareum. So you lost 30% on Friday, look at the buying pressure and support, MMs will play with it for a bit but the 3month outlook is a substantial rerate to double digits.

10years invested in Sareum and whilst I've seen the odd bit of negative news, this drop and subsequent buys show a support level and interest which I've certainly not witnessed before. It's going to a different level - an opportunity arose and it was jumped on by those who can see past next week. This should give you even more confidence in Sareum - whilst I do also consider Stach's concern over the TYK2 compounds MTD, Tim and our chairman put that to bed a few months back, formulation sorted - this is what will be holding up the CTA's.

Sar's news stream was too good to be true but if we could choose one to fall it would be the FLT3 program. Can't win it all it seems, whether or not the Chinese have been fair players is irrelevant now, lets just move forward with what we have and what is a driving the real interest in Sareum.

https://endpts.com/fda-stamps-fast-ok-on-astellas-pioneering-flt3-aml-drug-gilteritinib-expanding-on-a-record-year-for-new-approvals/

19,000 new AML cases each year linked to this mutation, Astellas selling theirs for $270,000 for a year of therapy..Do the math.

An NHS nurse who has contracted Covid-19 three weeks after being vaccinated says she is "angry and heartbroken".

https://www.bbc.co.uk/news/uk-wales-55579028

Not that this is essentially good news for humanity or getting us out of this mess, I think it is expected and should allow us all to realize that there is no silver bullet, no immediate end in sight and as Patrick Vallance stated, we will be treating COVID for years to come.

Well here is more evidence, if we needed it that Sareum are right on the cusp of greatness.
https://www.sciencemediacentre.org/expert-reaction-to-preprint-from-the-remap-cap-trial-looking-at-tocilizumab-and-sarilumab-in-critically-ill-covid-19-patients/

The powers to be will be well aware of our tyk2/jak1, certainly room for improvement and a really unbelievable turn of events for Sareum, our study will be very closely watched and the hint of positivity will propel this live-saving drug straight to where it needs to be.

We're about to produce some amazing results from years of molecule research and testing.

Agree Thoth, I posted about this too in the early hours but lost with the excitement today.
Full picture should emerge with SRA737 I'll say this quarter,..
Single digits soon to be gone forever. It's been worth the wait.

Fadec, I'm not sure what your refering too? Have you misread me or misinterpreted?

Now I'd like to see John Reader engaged for the phone interview, since it is official. Always a great speaker.
First in class cancer treatment for what Don Nicholson stated "If you don't have a TYK2 then you haven't been paying attention".
Plenty validation and I'm sure plenty potential partners. We will be moving through the gears this quarter.
Stage is setup very nicely.
Good luck all.

Well 1 out of 2 ain't bad. But the day is not over yet..

Utah, if not, we are still in the most exciting period of Sareum, ever. We've waited a long time for this, so enjoy it.

Hi Utah, I posted a while back about my anticipation for the 7th, obviously nothing concrete just a few dates and said timescales lined up with today based on what I was reading and interpreting.
Sierra sitting on SRA737 is almost criminal.

Sierra should be announcing their hand shortly imo:
http://filecache.investorroom.com/mr5ircnw_sierra/248/SRA737%20LDG%20IO%20Combo%20AACR%202019_FINAL.pdf

Our CHK1 combo should be advancing soon, Sierra will be very interested in this news I would imagine:
https://www.fiercepharma.com/marketing/opdivo-s-small-cell-lung-cancer-no-more-as-bristol-myers-pulls-nod-trial-failure

Sorry to hear that - let's hope the 7th is our day then, I'll pick you up on the way.